Home / 2020 / March / 09

Daily Archives: March 9, 2020

Woodbridge by Robert Mondavi Wines Announces New Major League Baseball Partnership

No. 3 Glass Wine Brand in U.S.* Partners with MLB in its First League-Wide Deal

LODI, Calif., March 09, 2020 (GLOBE NEWSWIRE) — Woodbridge by Robert Mondavi Wines and Major League Baseball today announced a new multi-year sponsorship agreement making Woodbridge Wines the Official Wine of MLB. The new partnership brings together two iconic American brands recognized for their pioneering spirit and legendary figures, and marks the first time Woodbridge Wines has partnered with a U.S. sports league. The number-three glass wine brand in the United States* will support the partnership nationally and regionally through MLB Club partnerships with the New York Yankees, Los Angeles Dodgers, Boston Red Sox, Houston Astros and Cincinnati Reds, and a 360-marketing plan, and will introduce packaging featuring MLB marks on select Woodbridge Wines in 2021.

On a national scale, Woodbridge Wines will promote new creative for its “From One For All” campaign with TV advertisements running during MLB games on MLB Network, ESPN and other national broadcast partners. Building on this successful campaign, Woodbridge Wines will also introduce a special MLB tagline, ‘A Legendary Wine for a Legendary Game,’ which will be featured in point of sale, advertising and retail executions, as well as highlighted through integrated branding across MLB Network. Woodbridge Wines will also have a presence at marquee events including All-Star Week and the World Series.

Locally, Woodbridge Wines will bring the excitement of the ballpark to life at retail locations across the country through unique baseball themed in-store merchandising and a national consumer sweepstakes offering a chance to win an unforgettable baseball experience.  The brand will also amplify its presence with new specialty baseball-themed wine cocktails and through awareness generating digital campaigns, out-of-home and radio advertising.

“Woodbridge by Robert Mondavi and MLB are two widely respected, beloved brands with loyal fans and historical significance in American culture,” said Jaymie Schoenberg, Vice President of Marketing, Woodbridge by Robert Mondavi Wines. “At Woodbridge Wines, we remain committed to our founder Robert Mondavi’s vision of making quality California wines of exceptional value accessible to all. Similar to Woodbridge Wines’ legacy, baseball is rich in tradition and has become an American institution celebrated for bringing people together over a shared interest while delivering a high-quality experience. Through this partnership with MLB, we are excited to bring our existing fans a unique new way to enjoy Woodbridge Wines while taking in their favorite pastime, as well as introduce new baseball lovers to our award-winning portfolio.”

With 40 years of history dedicated to making quality wines for everyday enjoyment, Woodbridge Wines founder Robert Mondavi helped establish California’s reputation for quality winemaking on a global scale and encouraged a growing wine culture in the U.S. by creating a wine for all people. Woodbridge Wines is excited to bring Robert Mondavi’s pioneering spirit and “From One For All” mentality to baseball by becoming the Official Wine of MLB.

“Partnering with Woodbridge Wines, such a well-respected company and leader in its space, provides MLB and our millions of fans a variety of unique opportunities,” said Noah Garden, MLB Executive Vice President, Business & Sales. “We look forward to working with the Woodbridge team on the development and execution of a range of engaging marketing activations throughout our partnership.”
*i6 Report MULO+C L52wks ending 2-23-20

About Woodbridge
Robert Mondavi founded Woodbridge Winery near his childhood home in Lodi, California to make quality wines accessible to wine lovers across the world to enjoy as part of daily life. Mr. Mondavi’s pioneering vision for Woodbridge by Robert Mondavi has raised the standard for everyday wines in America, and has made Woodbridge one of the most beloved wines in the U.S. The trusted heritage and quality of Woodbridge by Robert Mondavi ensures you don’t need to spend more for great wine and the diverse portfolio of classic wines marked by bright fruit flavors made to complement food means there is something for everyone. For more about Woodbridge by Robert Mondavi, including food and wine pairings and recipes ideas, please visit www.WoodbridgeWines.com.

About Major League Baseball

Major League Baseball (MLB) is the most historic professional sports league in the United States and consists of 30 member clubs in the U.S. and Canada, representing the highest level of professional baseball. Led by Commissioner Robert D. Manfred, Jr., MLB currently features record levels of labor peace, competitive balance and industry revenues, as well as the most comprehensive drug-testing program in American professional sports. MLB remains committed to making an impact in the communities of the U.S., Canada and throughout the world, perpetuating the sport’s larger role in society and permeating every facet of baseball’s business, marketing and community relations endeavors. With the continued success of MLB Advanced Media and MLB Network, MLB continues to find innovative ways for its fans to enjoy America’s National Pastime and a truly global game. For more information on Major League Baseball, visit www.MLB.com.

 Contact: David Hochman, Major League Baseball, (212) 931-7878, MLBPressBox.com@MLB_PR
Kara Larmie, Woodbridge by Robert Mondavi, Kara.Larmie@CBrands.com

 

AT&T to Deploy the Synchronoss Personal Cloud Solution

Comprehensive solution will give AT&T subscribers the ability to safely back up valuable personal content from any Android smartphone through a value-added cloud service

BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging, digital and IoT products, today announced that it is powering AT&T Personal Cloud, a new service for AT&T Mobility wireless customers. The Synchronoss solution will integrate into a suite of selected AT&T services, using the cloud to vastly improve the subscriber’s overall experience. It will also give AT&T the ability to provide a new value-added services to its wireless customers.

AT&T will offer its version of the Synchronoss Personal Cloud solution as a standalone value-added service that will integrate with the following AT&T cloud-based services:

  • AT&T Mobile Transfer – The Synchronoss integration will give users of the AT&T Mobile Transfer app, a free service that enables the easy transfer of content from one device to another, the option to enroll in the AT&T Personal Cloud service. This will extend AT&T’s ability to support and protect subscriber content by ensuring that it is safely transferred and backed up.
  • AT&T Setup & Transfer (Out Of Box Experience) – Functionality provided by Synchronoss, which was previously announced in mid-2019, gives subscribers using AT&T’s  onboarding experience the ability to simply self-select value-added products and services during the device setup process.

Glenn Lurie, President and CEO at Synchronoss, said, “Operators today must provide their customers with enhanced products and services that will continually improve their overall experience. The Synchronoss Personal Cloud solution accomplishes this by automating device back up  and simplifying how customers manage and interact with their content.  This allows AT&T the ability to bring new services to customers.”

“The ability to offer a secure personal cloud capability has become increasingly critical to global operators,” said Lurie. “By deploying the Synchronoss Personal Cloud solution, AT&T is significantly improving the customer experience. Embedding cloud into its out-of-box device set-up experience, enhancing content transfer services, and providing easy access to much-needed cloud-based data back up puts AT&T in the driver’s seat when it comes to meeting customer needs, increasing customer engagement and driving new revenue.”

“AT&T Personal Cloud is important in providing our subscribers with the means to store, transfer and access their personal content via mobile devices,” said Kevin Petersen, SVP Wireless Product Marketing. “The Synchronoss solution gives us the ability to integrate these benefits into our own services – a tremendous benefit both for subscribers, who would prefer to manage their services digitally, and for AT&T given the benefits that come from increased customer satisfaction.”

To find out more about Synchronoss’ Personal Cloud solution, visit the Synchronoss website cloud solutions page at https://synchronoss.com/solutions/cloud/

About Synchronoss Technologies, Inc.
Synchronoss (NASDAQ: SNCR) transforms the way companies create new revenue, reduce costs and delight their subscribers with cloud, messaging, digital and IoT products and platforms supporting hundreds of millions of subscribers across the globe. Synchronoss’ secure, scalable and groundbreaking new technologies, trusted partnerships and talented people change the way TMT customers grow their businesses. For more information, visit us at www.synchronoss.com.

Contacts
Investors
Joseph Crivelli
Synchronoss
908-566-3131
investor@synchronoss.com

Media
Anais Merlin
CCgroup (International)
T: +44 20 3824 9200
E: synchronoss@ccgrouppr.com

Diane Rose
CCgroup (North America)
T: +1 727.238.7567
E: diane@ccgrouppr.com

Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials

VANCOUVER, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has made the decision to begin production of NP-120 (Ifenprodil) with a new injectable and long acting oral release formulation, in order to be prepared for new US clinical trials for COVID-19 (coronavirus) and acute lung injury (ALI).

The decision was made after a recent independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. This compelling data, generated via a genome wide RNAi interference approach, that lead the investigators to the identification of Ifenprodil, an NMDA receptor antagonist, has been a major contributing factor in the Company’s decision.

The Company is in negotiations with a number of manufacturers and will be announcing more details on its decision shortly.

“The Company believes strongly in the potential of Ifenprodil to treat patients who have a severe acute lung injury, including people who have various forms of respiratory infections including COVID-19 (coronavirus) and influenza,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon has filed new intellectual property rights for NP-120 (Ifenprodil) for the treatment of respiratory diseases.

About NP-120 (Ifenprodil)

NP-120 (Ifenprodil) is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. Although the anti-fibrotic activity of Ifenprodil in IPF is not known, recent studies have suggested a link between both receptors and pathways associated with fibrosis.

Glutamate (Glu) is the main excitatory neurotransmitter which acts on glutamate receptors in the central nervous system (CNS) but overactivation of these receptors can cause several damages to neural cells including death. Recent studies show that the glutamate agonist N-methyl-d-aspartate (NMDA) can trigger acute lung injury (ALI). ALI is a direct and indirect injury to alveolar epithelial cells and capillary endothelial cell, causing diffuse pulmonary interstitial and alveolar edema and acute hypoxic respiration failure. ALI is characterized by reduced lung volume and compliance, and imbalance of the ventilation/perfusion ratio, inducing hypoxemia and respiratory distress and its severe stage (oxygen index <200) known as acute respiratory distress syndrome (ARDS). (1) Furthermore, pathological findings show that 64% of ARDS patients may have pulmonary fibrosis during convalescence (2).

NP-120 (Ifenprodil – brand name Cerocal) was initially developed by Sanofi in the 1990s in the French and Japanese markets for the treatment of circulatory disorders. The drug is genericized and sold in Japan.

About Algernon Pharmaceuticals Inc. 

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and chronic cough.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938426/
  2. https://www.ncbi.nlm.nih.gov/pubmed/19909524

QRails Backed by Global Equities Asset Manager in Series A Funding Round

EFM Asset Management Supports Payment Processor as Major Program Launches Take Shape for 2020

DENVER, March 09, 2020 (GLOBE NEWSWIRE) — QRails, a cloud-based, open API issuer-processor that enables innovative payment solutions around the world, today announced the closing of a $8 million Series A funding round led by EFM Asset Management. The announcement comes as QRails, in partnership with payroll service providers, is about to launch a novel earned wage access solution in the United States, UK and Australia. This fundraising round brings total funds raised to date by QRails to $18 million.

Less than a year after launching its processor and after co-founder Gerard Griffin took the helm as CEO, QRails has won significant customer mandates on the strength of its technology, its domain knowledge and its commitment to customer service. QRails customers include fintechs, banks, and insurance companies. The company is about to launch an innovative instant pay solution, available on a white-label basis to human capital management, workforce capital management and payroll processing platforms in the United States, Europe, and Australia. With its first customer, QRails will be providing instant access to accrued wages to 1.5 million hourly employees, enabling up to $20 billion in annual payments when the solution is fully deployed.

“This round of funding will support further growth at QRails. It comes at a pivotal moment for us,” commented Griffin. “We are immensely excited to be rolling out our earned wage access solution in the US and to be establishing a presence in Australia later this summer. We look forward to continuing to power payments innovation within financial services, including instant wage payments, open banking and the digital payment of insurance claims.”

Jeff Emmanuel, Chief Investment Officer and founder of EFM, added, “We are focused on identifying technology platforms whose innovations create seamless experiences for businesses and end-users. Our disruptive fintech fund invests in dynamic companies which leverage their capabilities to deliver improved customer outcomes. We are excited to partner with QRails and their world-class team at a stage in their development, and for the issuer processing industry generally, where we expect significant growth. We look forward to leveraging our network and experience to maximize this opportunity.”

QRails is headquartered in Denver, CO with an office in London. It plans to open an office in Sydney later this year.

About QRails
QRails enables payroll service providers, fintechs, banks, insurance companies, and other financial services businesses in North America and Europe to deploy innovative payment solutions. QRails clients benefit from purpose-built technology offering secure and flexible APIs as well as easy access to an expert team committed to delivering responsive customer service. Founded in 2016, QRails, Inc., together with its subsidiaries QRails, Ltd. (London, UK) and Rete-Pay, is privately held by a group of industry leaders and leading investors. Learn more at www.QRails.com.

MEDIA CONTACT
Shannon Furey
shannon@mdidit.com
732-721-0890 – ext. 105 (office)
732-995-1638 (mobile)

Biotalys ประกาศปิดรอบที่สองของรอบการจัดหาเงินทุน Series C €45 ล้าน

Biotalys ได้ระดมเงินเพิ่มเติมอีก €10 ล้าน เพื่อต้อนรับ Novalis LifeSciences ผู้เชี่ยวชาญด้านการลงทุนจากสหรัฐฯ

เกนต์, เบลเยี่ยม, March 09, 2020 (GLOBE NEWSWIRE) — Biotalys NV บริษัทด้านการป้องกันอาหารและพืชผลที่กำลังเติบโตและเปลี่ยนแปลงอย่างรวดเร็ว ซึ่งกำลังพัฒนาโซลูชันไบโอคอนโทรลที่ใช้โปรตีนรุ่นใหม่ วันนี้ได้ประกาศปิดรอบที่สองของรอบการจัดหาเงินทุน Series C มูลค่า €10 ล้าน ทำให้จำนวนเงินทุนทั้งหมดที่ระดมทุนผ่าน Series C สูงถึง €45 ล้าน

การปิดรอบที่สองของ Series C ได้รับการสนับสนุนจากผู้ถือหุ้นในปัจจุบันและรวมถึงจากผู้ลงทุนที่มีความเชี่ยวชาญรายใหม่ Novalis LifeSciences Novalis LifeSciences เป็นบริษัทด้านการลงทุนและการให้คำปรึกษาสำหรับอุตสาหกรรมวิทยาศาสตร์ชีวภาพ ตั้งอยู่ใน Hampton, New Hampshire สหรัฐอเมริกา Marijn Dekkers อดีต CEO ของ Bayer AG และประธานของ Novalis LifeSciences จะร่วมเป็นคณะกรรมการบริหารของ Biotalys ในฐานะผู้สังเกตการณ์

Marijn Dekkers ประธานของ Novalis LifeSciences กล่าวว่า “Novalis LifeScience มีความสนใจในเทคโนโลยีชีวภาพที่ทันสมัยเป็นอย่างมากซึ่งสามารถทดแทนสารกำจัดศัตรูพืชสังเคราะห์ได้ โซลูชันไบโอคอนโทรลที่ใช้โปรตีนที่พัฒนาโดย Biotalys เป็นก้าวใหม่ของพัฒนาการสำหรับสารป้องกันอาหารและพืชผลแห่งอนาคตเหล่านี้ เราหวังเป็นอย่างยิ่งว่าจะได้เป็นส่วนหนึ่งของบริษัทที่น่าตื่นเต้นแห่งนี้”

เงินที่ได้จากการจัดหาเงินทุนจะนำไปใช้สำหรับการพัฒนา การลงทะเบียน และการผลิตในระดับเชิงพาณิชย์ของผลิตภัณฑ์สารฆ่าเชื้อราชีวภาพที่ทันสมัยที่สุดของ Biotalys และเพื่อขยายและสร้างแพลตฟอร์มการค้นพบที่ไม่เหมือนใครของบริษัทต่อไป การเปิดตัวสารฆ่าเชื้อราชีวภาพครั้งแรกมีกำหนดการในปี 2022 ในตลาดผักและผลไม้ในสหรัฐอเมริกา นอกจากนั้น เงินทุนยังจะถูกใช้เพื่อสนับสนุนการพัฒนาที่เร็วยิ่งขึ้นของสายการผลิตของผลิตภัณฑ์ที่เป็นนวัตกรรม ด้วยการใช้งานในศัตรูและโรคในพืชที่สำคัญ

“ในฐานะตัวแทนของผู้ถือหุ้นทั้งหมดของ Biotalys เราขอต้อนรับ Novalis LifeSciences ผู้ลงทุนจากสหรัฐอเมริกาของเราอย่างอบอุ่น Marijn Dekkers จะเพิ่มความเชี่ยวชาญในอุตสาหกรรมเกษตรในวงกว้างให้กับคณะกรรมการที่กระตือรือร้นของเราและช่วยให้เราผลักดันบริษัทให้ก้าวไปอีกระดับ Biotalys มีความก้าวหน้าอย่างมากในการค้นพบและพัฒนาสายการผลิตที่แข็งแกร่งของไบโอคอนโทรอันทันสมัย ตอบสนองความต้องการของเกษตรกรและผู้บริโภคที่มีการพัฒนาอย่างรวดเร็ว บริษัท AgTech ที่จะพลิกโฉมวงการจะทำตามคำสัญญา” Lieven De Smedt ประธานกรรมการของ Biotalys กล่าวเสริม

เกี่ยวกับ Biotalys

Biotalys คือบริษัทด้านการป้องกันอาหารและพืชผลที่กำลังเติบโตและเปลี่ยนแปลงอย่างรวดเร็ว ซึ่งกำลังพัฒนาโซลูชันไบโอคอนโทรลที่ใช้โปรตีนรุ่นใหม่ เพื่อการกำหนดอนาคตของการจัดหาอาหารที่ยั่งยืนและปลอดภัย

ด้วยแพลตฟอร์มเทคโนโลยีอันล้ำสมัย บริษัทได้พัฒนาผลิตภัณฑ์ที่มีประสิทธิภาพและปลอดภัยด้วยโหมดการทำงานที่แปลกใหม่ การจัดการศัตรูพืชและโรคพืชสำคัญตลอดห่วงโซ่คุณค่าทั้งหมด ตั้งแต่จากบนดินจนถึงในจาน

ไบโอคอนโทรลอันเป็นเอกลักษณ์ของ Biotalys ได้รวมคุณสมบัติที่มีประสิทธิภาพสูงและความเสมอต้นเสมอปลายของสารเคมีเข้ากับโปรไฟล์ความปลอดภัยที่สะอาดของสารชีวภาพ ทำให้เป็นสารป้องกันพืชผลที่เหมาะสำหรับการใช้งานทั้งก่อนและหลังการเก็บเกี่ยว บริษัทกำลังดำเนินการเพื่อเปิดตัวยาฆ่าเชื้อราชีวภาพแรกของบริษัท ที่สหรัฐอเมริกาในปี 2022 และจะทำการเปิดตัวกับตลาดโลกหลังจากนั้น

Biotalys ก่อตั้งในปี 2013 โดยแยกออกจาก VIB (Flanders Institute for Biotechnology) และได้สร้างมูลค่าจำนวน € 61 ล้านจนถึงปัจจุบันจากนักลงทุนท้องถิ่นและต่างชาติที่มีความเชี่ยวชาญ บริษัทตั้งอยู่ในกลุ่มเทคโนโลยีชีวภาพในเมืองเกนต์ ประเทศเบลเยียม สำหรับรายละเอียดเพิ่มเติม สามารถเยี่ยมชมได้ที่ www.biotalys.com

สำหรับรายละเอียดเพิ่มเติม โปรดติดต่อ

Marieke Vermeersch ที่ปรึกษาด้านการสื่อสารองค์กร
โทร: +32 (0)9 261 06 84
อีเมล: marieke.vermeersch@biotalys.com

150 Machang PKR branch members quit party

sMACHANG, March 7 — A total of 150 members of the Machang PKR branch have quit the party today.

Its former deputy chief Md Ziferibin Manan said the group was part of the branch’s 1,800 registered members.

“We quit the party voluntarily without coercion from anyone as we are disappointed with PKR president Datuk Seri Anwar Ibrahim’s leadership.

“The number of members quitting the party is expected to increase from time to time,” he told Bernama at the farewell do held at Machang PKR branch here today.

He said their struggles were futile as they only served the wishes of the president and the interests of some individuals in PKR.

“This move was also due to party’s infighting that affected members, and at the same time causing the people to lose confidence in PKR.

“Members who quit the party today are free to assist the community through various non-governmental organisations (NGOs),” he said.

Source: BERNAMA (News Agency)

PAS to wait for cabinet formation before discussing power-sharing with UMNO

KOTA BHARU, March 7 — PAS wants to wait for the formation of the Federal Cabinet before discussing matters relating to power-sharing in states it controls with UMNO, said PAS vice-president Datuk Amar Nik Abdullah.

“We want to make sure the administration of the country is going smoothly first, particularly to solve the economic issues.

“The matter (power-sharing) with UMNO is a secondary issue,” he told reporters here today.

PAS currently controls the states of Kelantan and Terengganu.

In another development, Mohd Amar urged all quarters to respect the Yang di-Pertuan Agong Al-Sultan Abdullah Ri’ayatuddin Al-Mustafa Billah Shah’s decision to appoint Tan Sri Muhyiddin Yassin as the 8th Prime Minister.

“The appointment was made based on law and His Majesty used his discretion after being advised by legal experts.

“Therefore, the King’s decision should not be disputed,” he said.

Source: BERNAMA (News Agency)